Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13Neoplasm Metastasis 2Recurrence 1Hormone Receptor Positive Breast Carcinoma 1HER2-positive Metastatic Breast Cancer 1Genetic Diseases, Inborn 1Endometrial Neoplasms 1Carcinoma, Ductal, Breast 1Advanced HER2+Breast Cancer 1Advanced Breast Cancer 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Gemcitabine 6Cisplatin 6Bortezomib 6venetoclax 5elotuzumab 4isatuximab 3blinatumomab 3Vincristine 3Radiotherapy 3Prednisone 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2ixazomib 2dexamethasone 21-phosphate 2cabazitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × Alpelisib × Clear all
NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡